BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

SARS-CoV-2, neutralizing antibody diagram

Siemens Healthineers leads effort to define COVID-19 immunity with CDC, JRC

Sep. 15, 2020
By Annette Boyle
Siemens Healthineers AG snagged a key role in the mystery playing out across the world's pandemic stage – what do antibody test results mean in terms of immunity to SARS-CoV-2 and how do different tests assessing different proteins compare? The U.S. CDC and the Joint Research Centre (JRC) of the European Commission tapped the Erlanger, Germany-based company to take the lead in developing a process to standardize antibody assays.
Read More

Regulatory actions for Sept. 15, 2020

Sep. 15, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cerapedics, Controlrad, Eurobio Scientific, Fibralign, GE Healthcare, Genmark Diagnostics.
Read More

Other news to note for Sept. 15, 2020

Sep. 15, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Anpac Bio-Medical Science, Apple, Bostongene, Cardiacsense, Chest Foundation, Concept Medical, Controlrad, Fujifilm Sonosite, Genetic Technologies, Global Plasma Solutions, Illumina, Movendo, Nihon Kohden, Palisade, Polyganics, Sherlock Biosciences, Ursa Health, Visage, Welldoc.
Read More
U.S. vaccine illustration

U.S. vaccine plan can’t be just about COVID-19

Sep. 15, 2020
By Mari Serebrov
What’s the plan? The U.S. CDC is being asked that question a lot these days – not just about COVID-19, but also about preparing for what could be a tough influenza season as flu bugs circulate with the coronavirus.
Read More
Regulatory front

FDA releases guidance on COVID-19, geriatric labeling, EoE

Sep. 15, 2020
By Mari Serebrov
The latest global regulatory news, changes and updates affecting biopharma, including: NIH adds funding to Latino Alzheimer’s research; Sprout warned for Addyi promotion; Scripps to pay $10M over use of NIH grants.
Read More

Regulatory actions for Sept. 15, 2020

Sep. 15, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aerie, Amryt, Apellis, Ardelyx, Astrazeneca, BMS, Boehringer, Epimab, Equillium, Gensight, Gilead, Kiniksa, Lilly, Mateon, Matinas, Novartis, Plus, Takeda, Zynerba.
Read More

Other news to note for Sept. 15, 2020

Sep. 15, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adicet, Alimera, Anelixis, Applied Stemcell, Axovant, Bayer, Biontech, BMS, Bostongene, C3.ai, Cell and Gene Therapy Catapult, Cellinta, Combigene, Corino, Cullinan, Cue, ERS Genomics, Exelixis, Fosun, Genexine, Humanigen, Iconic, Innovation Pharma, Kiadis, Mabion, Medis, Melior, Mindset, Miragen, Momenta, Mylan, Novavax, Novus, Obsidian, Oligomerix, Pfizer, Protokinetix, Restorbio, Serum Institute of India, Soligenix, Systems Oncology, Teva, Tonix, Vaxine.
Read More

In the clinic for Sept. 15, 2020

Sep. 15, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adocia, Aerpio, Arbutus, Atossa, Atyr, Axsome, Clinuvel, Codiak, Curasen, Curevo, Galecto, Kyorin, Marinus, Opko, Teva, TFF, Tyme.
Read More

Other news to note for Sept. 14, 2020

Sep. 14, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Applied Spectral Imaging, Astrazeneca, Avita Therapeutics, Bio-Techne, Guided Therapeutics, Kantaro Biosciences, Luminultra, Meridian, Mimedx, Mount Sinai Health, Natera, Nevro, Shandong Yaohua Medical Instrument, Staar Surgical, Telo Genomics, Thermo Fisher Scientific, Transenterix.
Read More

Celltrion advancing COVID-19 antibody treatment CT-P59 and trials continue

Sep. 14, 2020
By Gina Lee
HONG KONG – Interim results of a phase I study CT-P59, an anti-COVID-19 monoclonal antibody being developed by Incheon, South Korea-based Celltrion Inc., have confirmed the candidate’s safety, tolerability and pharmacokinetics in healthy subjects, giving the company confidence to ramp up production of the experimental antiviral.
Read More
Previous 1 2 … 373 374 375 376 377 378 379 380 381 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing